drugset / Trial / NCT02947061
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the progression free survival(PFS) and safety of TS-S vs. TX-X in Patients With Advanced Breast Cancer first-line treatment
Timeline
- Start
- 2015-04
- Primary completion
- 2017-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | S-1 | Small molecule | 80 mg | — |
| Subject | S-1 | Small molecule | 120 mg | — |
| Background | Docetaxel | Small molecule | 75 mg/m2 | — |